Can-Fite Shareholders Face Key Decisions as Annual Meeting Gets Second Date

Rhea-AI Filing Summary

Can-Fite BioPharma announced the adjournment of its Annual General Meeting of Shareholders originally scheduled for June 23, 2025, due to lack of quorum. The meeting has been rescheduled for June 30, 2025, at 3:00 p.m. Israel time and will be held at the company's offices in Ramat Gan, Israel.

The Form 6-K was signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer of the company. This regulatory filing fulfills the company's obligation to report material events to shareholders under Securities Exchange Act requirements.

Positive

• None.

Negative

• Annual General Meeting failed to achieve quorum, indicating potential shareholder engagement issues

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of June 2025

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒           Form 40-F ☐

 

 

 

 

 

On June 23, 2025, Can-Fite BioPharma Ltd. (the “Company”) convened the Annual General Meeting of Shareholders (the “Annual General Meeting”), however, the Annual General Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company’s Annual General Meeting will be reconvened on Monday, June 30, 2025 at 3:00 p.m., Israel time at the Company’s offices located at 26 Ben Gurion Street, Ramat Gan, Israel.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: June 23, 2025	By:	/s/ Motti Farbstein
 	 	Motti Farbstein
 	 	Chief Executive Officer and Chief Financial Officer

 

 

2

 

FAQ

When is CANF's rescheduled Annual General Meeting in 2025?

CANF's Annual General Meeting has been rescheduled to Monday, June 30, 2025 at 3:00 p.m. Israel time, to be held at the Company's offices at 26 Ben Gurion Street, Ramat Gan, Israel.

Why was CANF's Annual General Meeting on June 23, 2025 adjourned?

CANF's Annual General Meeting on June 23, 2025 was adjourned for one week due to lack of quorum.

Who is the current CEO and CFO of CANF as of June 2025?

Motti Farbstein serves as both Chief Executive Officer and Chief Financial Officer of Can-Fite BioPharma Ltd.

What type of annual reports does CANF file with the SEC?

CANF files Form 20-F annual reports with the SEC, as indicated in their 6-K filing.